TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35044272

Group type: EXPERIMENTAL
Intervention: Cosyntropin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Vigabatrin
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cosyntropin and Vigabatrin combined
Number of subjects: 34
Study: 34540188

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 ?g/kg loading dose for 15 min, followed by 0.4 ?g/kg/h until 30 min before surgery)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (saline administered in the same manner)
Number of subjects: 174
Study: 33605677

Group type: EXPERIMENTAL
Intervention: Stent+HIFUA
Number of subjects: 92

Group type: COMPARATOR
Intervention: Stent-only
Number of subjects: 92
Study: 35461788

Group type: EXPERIMENTAL
Intervention: Early bedtime condition (9.5 hours sleep opportunity)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Late bedtime condition (6.5 hours sleep opportunity)
Number of subjects: 90
Study: 33851255

Group type: EXPERIMENTAL
Intervention: Monophasic HA filler (Sardenyashape®)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Biphasic HA filler (Restylane LYFT®)
Number of subjects: 96
Study: 34406530

Group type: EXPERIMENTAL
Intervention: Early allopurinol initiation (day 1)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Late allopurinol initiation (day 14)
Number of subjects: 117
Study: 33002598

Group type: EXPERIMENTAL
Intervention: NU-HOME program (family meals-focused program)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 114
Study: 32734691

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 692

Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 692
Study: 35611683

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 34256819

Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 309

Group type: COMPARATOR
Intervention: 7 + 3
Number of subjects: 309
Study: 36361239

Group type: EXPERIMENTAL
Intervention: Stroop test (15 min, 600 tasks, 5 colors)
Number of subjects: 64
Study: 34407724

Group type: EXPERIMENTAL
Intervention: Father-child dyads
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control dyads (randomly paired signals)
Number of subjects: 29
Study: 34330857

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) sessions with a trained social worker, 4-5 sessions over approximately 4 weeks.
Number of subjects: 16
Study: 33155754

Group type: EXPERIMENTAL
Intervention: ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)
Number of subjects: 771

Group type: COMPARATOR
Intervention: BEACOPP escalated plus BEACOPP baseline (4 + 4 courses)
Number of subjects: 771

Group type: COMPARATOR
Intervention: BEACOPP escalated plus BEACOPP baseline (4 + 4) and Rituximab
Number of subjects: 771
Study: 35831176

Group type: EXPERIMENTAL
Intervention: IVT+EVT
Number of subjects: 539

Group type: COMPARATOR
Intervention: EVT alone
Number of subjects: 539
Study: 34680123

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) adjunctive therapy (16 mg/mL cross-linked and 2 mg/mL non-cross-linked)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-surgical periodontal therapy without HA)
Number of subjects: 0
Study: 34391978

Group type: EXPERIMENTAL
Intervention: Home-based telemedicine (HBT) delivery of Prolonged Exposure (PE)
Number of subjects: 136

Group type: COMPARATOR
Intervention: In-person delivery of Prolonged Exposure (PE)
Number of subjects: 136
Study: 32483134

Group type: EXPERIMENTAL
Intervention: Atorvastatin (single 80-mg oral dose)
Number of subjects: 60
Study: 34229675

Group type: EXPERIMENTAL
Intervention: Communication skills and self-efficacy training for healthcare workers (4 sessions of 90 minutes each)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Communication skills and self-efficacy training for healthcare workers
Number of subjects: 105
Study: 35457480

Group type: EXPERIMENTAL
Intervention: SST + TPE
Number of subjects: 157

Group type: COMPARATOR
Intervention: SST
Number of subjects: 157
Study: 32304405

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (50 mg/kg loading dose for 15 min, followed by 15 mg · kg · h infusion)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 120
Study: 33570279

Group type: EXPERIMENTAL
Intervention: Error management trainings
Number of subjects: 656

Group type: COMPARATOR
Intervention: Missing trainings on error management
Number of subjects: 656

Group type: COMPARATOR
Intervention: Documentation errors
Number of subjects: 656
Study: 33079884

Group type: EXPERIMENTAL
Intervention: Oxycodone (0.1 mg/kg initial dose, adjusted by 10% based on analgesia adequacy)
Number of subjects: 113
Study: 35384093

Group type: EXPERIMENTAL
Intervention: Liberal oral intake immediately after discharge from PACU
Number of subjects: 174

Group type: COMPARATOR
Intervention: Traditional oral intake 6 hours after discharge from PACU
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Liberal oral intake
Number of subjects: 174

Group type: COMPARATOR
Intervention: Traditional oral intake
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 174
Study: 33901689

Group type: EXPERIMENTAL
Intervention: 10 % Nisin with MTAD
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1.3 % NaOCl and MTAD
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2.5 % NaOCl and 17 % EDTA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PDT with MTAD
Number of subjects: 40
Study: 32555601

Group type: EXPERIMENTAL
Intervention: True-immunized (n=21) with 810-1235 infected bites
Number of subjects: 26

Group type: COMPARATOR
Intervention: Mock-immunized (n=5)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: True-immunized (n=10) with 839-1131 infected bites in Cohort 2
Number of subjects: 26

Group type: COMPARATOR
Intervention: Mock-immunized (n=2) in Cohort 2
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: True-immunized subjects administered three booster immunizations
Number of subjects: 26

Group type: COMPARATOR
Intervention: Controls (n=6)
Number of subjects: 26
Study: 36372813

Group type: EXPERIMENTAL
Intervention: On-demand removal (ODR) of syndesmotic screws
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine removal (RR) of syndesmotic screws
Number of subjects: 0
Study: 33143639

Group type: EXPERIMENTAL
Intervention: Preinstalled nasopharyngeal airway (NPA) in the right nasal passageway
Number of subjects: 108

Group type: COMPARATOR
Intervention: NGI via the right nostril (Group O)
Number of subjects: 108
Study: 33977796

Group type: EXPERIMENTAL
Intervention: Anifrolumab (300 mg every 4 weeks for 48 weeks)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726
Study: 35599520

Group type: EXPERIMENTAL
Intervention: Osseo-densification technique using specialized (Densah) bur kit
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional technique using standard bur kit
Number of subjects: 20
Study: 32116251

Group type: EXPERIMENTAL
Intervention: Genetically DBP levels (per 1 standard deviation (SD) increase 50 mg/L)
Number of subjects: 0
Study: 34873082

Group type: EXPERIMENTAL
Intervention: Medical intervention for PCOS management over 3 months
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Medical intervention for PCOS management at 2 months
Number of subjects: 117
Study: 33717194

Group type: EXPERIMENTAL
Intervention: Zika purified-inactivated virus (ZPIV) vaccine, 3 doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zika purified-inactivated virus (ZPIV) vaccine in JEV pre-immunized individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zika purified-inactivated virus (ZPIV) vaccine in YFV pre-immunized individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zika purified-inactivated virus (ZPIV) vaccine in flavivirus-naïve individuals
Number of subjects: 0
Study: 35490585

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided stellate ganglion injection
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional blind puncture block
Number of subjects: 68
Study: 34794202

Group type: EXPERIMENTAL
Intervention: CitruSlim high-dose (HD, 400 mg)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: CitruSlim low-dose (LD, 200 mg)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 33836627

Group type: EXPERIMENTAL
Intervention: DigiKnowIt News (interactive, multimedia educational website)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Wait-list control group (no access to DigiKnowIt News during the study)
Number of subjects: 91
Study: 33221203

Group type: EXPERIMENTAL
Intervention: Brand with the fewest ingredients
Number of subjects: 722

Group type: COMPARATOR
Intervention: Other two brands of wipes
Number of subjects: 722
Study: 32568642

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (aspirin and clopidogrel)
Number of subjects: 932

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 932
Study: 36357712

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 34154636

Group type: EXPERIMENTAL
Intervention: Large-scale drinking water supply intervention
Number of subjects: 280000
Study: 32490740

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Children with UTI
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cystitis group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pyelonephritis group
Number of subjects: 75
Study: 35181113

Group type: EXPERIMENTAL
Intervention: Cabernet Sauvignon wines with origin information
Number of subjects: 112

Group type: COMPARATOR
Intervention: Cabernet Sauvignon wines without origin information
Number of subjects: 112
Study: 34412705

Group type: EXPERIMENTAL
Intervention: Exercise intervention group (INT) - physical exercise training programme at moderate-to-vigorous intensity, 1 h three times weekly for 8 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (CON) - encouraged to continue usual level of activity, offered training programme after 8 weeks
Number of subjects: 25
Study: 36270584

Group type: EXPERIMENTAL
Intervention: Total hepatic inflow occlusion (TIO)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Hemihepatic inflow occlusion (HIO)
Number of subjects: 258
Study: 34694750

Group type: EXPERIMENTAL
Intervention: Plastinated models
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 3D printed models
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Survey instrument
Number of subjects: 96
Study: 35299288

Group type: EXPERIMENTAL
Intervention: Vericiguat plus isosorbide mononitrate
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo plus isosorbide mononitrate
Number of subjects: 41
Study: 32128865

Group type: EXPERIMENTAL
Intervention: Comprehensive Reminder System based on the Health Belief Model (CRS‐HBM)
Number of subjects: 174
Study: 35657540

Group type: EXPERIMENTAL
Intervention: Plastibell device (PD)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Frenular artery preservation (FAP)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Frenular artery ligation (FAL)
Number of subjects: 206
Study: 32443348

Group type: EXPERIMENTAL
Intervention: Adductor canal block with periarticular infiltration (30 mL of 0.5% ropivacaine and 100 mcg of clonidine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Periarticular infiltration alone
Number of subjects: 0
Study: 35290169

Group type: EXPERIMENTAL
Intervention: Gimsilumab
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 32856870

Group type: EXPERIMENTAL
Intervention: Muscle Energy Techniques (METS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Active Range of Motion Exercises (AROM)
Number of subjects: 48
Study: 35481557

Group type: EXPERIMENTAL
Intervention: 5μT low-frequency electromagnetic field (LF-EMF) signal for 30 minutes
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 32
Study: 32638023

Group type: EXPERIMENTAL
Intervention: Children HIV-exposed uninfected (CHEU)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Children HIV-unexposed uninfected (CHUU)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: CHEU
Number of subjects: 428

Group type: COMPARATOR
Intervention: CHEU vs CHUU
Number of subjects: 428
Study: 33896333

Group type: EXPERIMENTAL
Intervention: M7583 at 80 mg (three days)/160 mg (full 28-day cycle), then 300 mg/day, 600 mg/day, 900 mg/day, and 300 mg twice daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: M7583
Number of subjects: 18
Study: 34124987

Group type: EXPERIMENTAL
Intervention: Topical erythropoietin (3000 IU/mL) four times a day
Number of subjects: 8
Study: 34716710

Group type: EXPERIMENTAL
Intervention: Dialogic book‐sharing (8 weekly group sessions)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 140
Study: 32403918

Group type: EXPERIMENTAL
Intervention: Modified Natural Cycle (mNC)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Artificial Cycle (AC)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Natural Cycle (NC)
Number of subjects: 129
Study: 34067295

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 20
Study: 32111767

Group type: EXPERIMENTAL
Intervention: 12-month exercise intervention
Number of subjects: 537
Study: 34839016

Group type: EXPERIMENTAL
Intervention: Osimertinib plus bevacizumab
Number of subjects: 155

Group type: COMPARATOR
Intervention: Osimertinib alone
Number of subjects: 155
Study: 34172060

Group type: EXPERIMENTAL
Intervention: Phased written health education combined with healthy diet
Number of subjects: 130

Group type: COMPARATOR
Intervention: Routine health education
Number of subjects: 130
Study: 32585261

Group type: EXPERIMENTAL
Intervention: Passive ultrasonic activation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: XP‐endo Finisher files
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: F‐file activation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Needle irrigation
Number of subjects: 80
Study: 35849545

Group type: EXPERIMENTAL
Intervention: Corneal wavefront-guided transPRK (CWFG)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wavefront-optimized transPRK (WFO)
Number of subjects: 71
Study: 33878282

Group type: EXPERIMENTAL
Intervention: Deprescribing anticholinergic medications (ACM) over 1 to 6 months with education directed at psychiatrists and clinical pharmacy support.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Restarting ACM for re-emergent EPS.
Number of subjects: 0
Study: 32527232

Group type: EXPERIMENTAL
Intervention: Glibenclamide (loading dose of 1.25 mg, followed by 0.625 mg every 8 hours for 5 days)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 306
Study: 34662000

Group type: EXPERIMENTAL
Intervention: Vitamin B6 (80 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 32770409

Group type: EXPERIMENTAL
Intervention: Bounce Back intervention
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Bounce Back intervention (moderate compliance)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Bounce Back intervention (high compliance)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control group (practice as usual)
Number of subjects: 326
Study: 33216791

Group type: EXPERIMENTAL
Intervention: Patient-centred, risk-guided approach to addressing risks identified via risk assessment during pregnancy (9 practices)
Number of subjects: 1579

Group type: COMPARATOR
Intervention: Usual care (7 practices)
Number of subjects: 1579
Study: 35291004

Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (30 mg/kg) and ethambutol (R30HZE)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High-dose rifampicin and levofloxacin (R30HZL)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard-dose rifampicin and ethambutol (R15HZE)
Number of subjects: 37
Study: 34215198

Group type: EXPERIMENTAL
Intervention: Pilates exercise program
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 110
Study: 34651349

Group type: EXPERIMENTAL
Intervention: APF + FGG
Number of subjects: 49

Group type: COMPARATOR
Intervention: APF + CM
Number of subjects: 49
Study: 34156917

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 249

Group type: COMPARATOR
Intervention: Physiologically predicted 'poor' adherence
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Lower arousal threshold (ArTH)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: High and low pharyngeal muscle compensation (Vcomp)
Number of subjects: 249
Study: 35131823

Group type: EXPERIMENTAL
Intervention: Treadmill-PBT (perturbation-based balance training)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Treadmill walking
Number of subjects: 140
Study: 34534800

Group type: EXPERIMENTAL
Intervention: 7-day internet-based cognitive behavioral therapy (CBT)
Number of subjects: 16
Study: 34432514

Group type: COMPARATOR
Intervention: Hydromorphone (0.1 mg/kg, IM) alone (group H)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hydromorphone (0.1 mg/kg, IM) with acepromazine (0.05 mg/kg, IM; group AH)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hydromorphone (0.1 mg/kg, IM) with dexmedetomidine (6 µg/kg, IM; group DH)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Hydromorphone (group H)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hydromorphone with acepromazine (group AH)
Number of subjects: 39
Study: 34053974

Group type: EXPERIMENTAL
Intervention: Direct technique with Clearfil DC Core (DC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirect technique with Clearfil DC Core (DC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct technique with Panavia V5 (PV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirect technique with Panavia V5 (PV)
Number of subjects: 0
Study: 35230749

Group type: EXPERIMENTAL
Intervention: GP40071 (GP‐Asp)
Number of subjects: 26

Group type: COMPARATOR
Intervention: NovoRapid Penfill (Novo‐Asp)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both GP40071 and NovoRapid
Number of subjects: 26
Study: 35020025

Group type: EXPERIMENTAL
Intervention: Posterior-only stabilization
Number of subjects: 58

Group type: COMPARATOR
Intervention: Global reconstruction through a single-stage all-posterior approach
Number of subjects: 58
Study: 33025002

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens
Number of subjects: 27347

Group type: COMPARATOR
Intervention: Estrogens plus medroxyprogesterone acetate
Number of subjects: 27347
Study: 34491225

Group type: EXPERIMENTAL
Intervention: Guppy fish, Pyriproxyfen (PPF), and Communication for Behavioral Impact (COMBI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Guppy fish and COMBI
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (standard vector control)
Number of subjects: 30
Study: 33792958

Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg/d)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 33268419

Group type: EXPERIMENTAL
Intervention: High-dose intravenous zinc (0.5 mg/kg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 36336851

Group type: EXPERIMENTAL
Intervention: Corticosteroid irrigation
Number of subjects: 222

Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 222

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Corticosteroid irrigation, Saline irrigation, No treatment
Number of subjects: 222
Study: 33441103

Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 0
Study: 35264692

Group type: EXPERIMENTAL
Intervention: Dichoptic movies (3 movies/week)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Patching (14 hours/week)
Number of subjects: 65
Study: 32273682

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg kg‐1
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg kg‐1
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control (baseline values at T0)
Number of subjects: 133
Study: 34718462

Group type: EXPERIMENTAL
Intervention: POC EID (onsite testing with the Alere q HIV‐1/2 Detect)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: SOC EID (off‐site testing at a public laboratory)
Number of subjects: 4000
Study: 35603904

Group type: EXPERIMENTAL
Intervention: Incident HPV infections
Number of subjects: 20529

Group type: EXPERIMENTAL
Intervention: Carcinogenic HPV types
Number of subjects: 20529

Group type: EXPERIMENTAL
Intervention: Noncarcinogenic HPV types
Number of subjects: 20529

Group type: EXPERIMENTAL
Intervention: All HPV types within each study cohort
Number of subjects: 20529
Study: 33827848

Group type: EXPERIMENTAL
Intervention: Full model including demographics, comorbidities, laboratory results, and vital signs
Number of subjects: 17086

Group type: EXPERIMENTAL
Intervention: Model including all demographics and comorbidities
Number of subjects: 17086

Group type: EXPERIMENTAL
Intervention: Model including only age
Number of subjects: 17086

Group type: EXPERIMENTAL
Intervention: Predicted mortality for patients aged 18 years
Number of subjects: 17086

Group type: EXPERIMENTAL
Intervention: Predicted mortality for patients aged 55 years
Number of subjects: 17086

Group type: EXPERIMENTAL
Intervention: Predicted mortality for patients aged 85 years
Number of subjects: 17086

Group type: EXPERIMENTAL
Intervention: Predicted mortality across all ages over the study period
Number of subjects: 17086
Study: 32713395

Group type: EXPERIMENTAL
Intervention: Nocturnal whey protein ingestion (63 g whey protein)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (water only)
Number of subjects: 15
Study: 35738686

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) for perfectionism
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 40
Study: 32303839

Group type: EXPERIMENTAL
Intervention: Laparoscopic myotomy (LM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Pneumatic dilatation (PD)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL)
Number of subjects: 43
Study: 34816612

Group type: COMPARATOR
Intervention: Control (n = 9)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT; n = 9)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT; n = 10)
Number of subjects: 28